Financial Results | Illumina 2025 Half-Year Revenue USD 2100.00 Million Net Income USD 366.00 Million
Illumina(ILMN) posted the Q2 of its 2025 financial results on 8/1/2025, reporting total revenue of USD 2100.00 million in the first half of the year, down 4.02% from USD 2188.00 million year over year, reporting net income of USD 366.00 million in the first half of the year, compare with the net income of USD -2114.00 million in the same period last year. The EPS is USD 2.32 in the first half of the year, compare with USD -13.28 last period.
[Detailed Data]
| Million USD | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Total Revenue | 1059.00 | 1041.00 | 1104.00 | 1080.00 |
| Cost of Sales | 364.00 | 358.00 | 376.00 | 335.00 |
| Gross Profit | 695.00 | 683.00 | 728.00 | 745.00 |
| Total Operating Expenses | 496.00 | 533.00 | 553.00 | 29.00 |
| Operating Income | 199.00 | 150.00 | 175.00 | 716.00 |
| Net Income | 235.00 | 131.00 | 187.00 | 705.00 |
| Net Income Attributable to Common Shareholders | 235.00 | 131.00 | 187.00 | 705.00 |
| EPS(USD) | 1.49 | 0.83 | 1.17 | 4.43 |
[Company Profile]
Illumina, Inc. is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. The company was incorporated in California in April 1998 and reincorporated in Delaware in July 2000. Using its proprietary technologies, the company provide a comprehensive line of genetic analysis solutions, with products and services that serve a broad range of highly interconnected markets, including sequencing, genotyping, gene expression, and molecular diagnostics. The company's customers include leading genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies.
Comentarios
Aún no hay comentarios